Verisante Technology, Inc. announced it has initiated communications with the Food and Drug Administration (FDA) in the United States for the approval of Aura, a device for the detection of skin cancer. Verisante has now submitted documents to the FDA as it begins the formal application process for approval to market and sell Aura in the United States.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0023 USD | -.--% | -.--% | +22,900.00% |
1st Jan change | Capi. | |
---|---|---|
+22,900.00% | 101K | |
+7.01% | 217B | |
+11.01% | 190B | |
+19.20% | 143B | |
+30.79% | 111B | |
+1.48% | 64.59B | |
+13.95% | 52.36B | |
-0.16% | 48.45B | |
-6.20% | 38.03B | |
+0.91% | 35.61B |
- Stock Market
- Equities
- VRSEF Stock
- News Verisante Technology Inc.
- Verisante Technology, Inc. Initiates Communications with FDA in the United States for the Approval of Aura